Cepheid (CPHD) Scheduled to Post Quarterly Earnings on Wednesday
Cepheid (NASDAQ:CPHD) will announce its earnings results after the market closes on Wednesday, October 12th. Analysts expect the company to announce earnings of $0.03 per share for the quarter. Cepheid has set its FY16 guidance at $0.31-0.34 EPS.
Cepheid (NASDAQ:CPHD) last issued its quarterly earnings results on Thursday, July 28th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.19. Cepheid had a negative return on equity of 10.20% and a negative net margin of 8.78%. The company earned $146 million during the quarter, compared to analyst estimates of $145.82 million. During the same period in the previous year, the company earned ($0.06) earnings per share. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. On average, analysts expect Cepheid to post $0.33 EPS for the current fiscal year and $0.96 EPS for the next fiscal year.
Cepheid (NASDAQ:CPHD) opened at 52.84 on Tuesday. Cepheid has a one year low of $25.09 and a one year high of $53.91. The firm’s market capitalization is $3.86 billion. The stock’s 50 day moving average price is $47.54 and its 200-day moving average price is $35.72.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/cepheid-cphd-scheduled-to-post-quarterly-earnings-on-wednesday.html
In other news, VP Scott A. Campbell sold 746 shares of the business’s stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $36.71, for a total transaction of $27,385.66. Following the completion of the transaction, the vice president now owns 10,721 shares of the company’s stock, valued at approximately $393,567.91. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 4.16% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. Principal Financial Group Inc. boosted its position in Cepheid by 0.9% in the second quarter. Principal Financial Group Inc. now owns 12,736 shares of the company’s stock worth $392,000 after buying an additional 119 shares during the period. ProShare Advisors LLC boosted its position in Cepheid by 9.2% in the second quarter. ProShare Advisors LLC now owns 11,310 shares of the company’s stock worth $348,000 after buying an additional 953 shares during the period. Rhumbline Advisers boosted its position in Cepheid by 3.3% in the second quarter. Rhumbline Advisers now owns 90,471 shares of the company’s stock worth $2,782,000 after buying an additional 2,890 shares during the period. Globeflex Capital L P acquired a new position in Cepheid during the second quarter worth approximately $145,000. Finally, Advisor Group Inc. acquired a new position in Cepheid during the second quarter worth approximately $145,000. 95.27% of the stock is owned by institutional investors.
A number of brokerages recently issued reports on CPHD. BTIG Research lowered Cepheid from a “buy” rating to a “neutral” rating in a research report on Wednesday, September 7th. Piper Jaffray Cos. lowered Cepheid from an “overweight” rating to a “neutral” rating in a research report on Tuesday, September 6th. Jefferies Group lifted their target price on Cepheid from $28.00 to $34.00 and gave the company a “hold” rating in a research report on Wednesday, August 17th. JPMorgan Chase & Co. lifted their target price on Cepheid from $32.00 to $35.00 and gave the company a “neutral” rating in a research report on Friday, July 29th. Finally, Robert W. Baird raised their price target on Cepheid from $44.00 to $53.00 and gave the company an “outperform” rating in a research note on Wednesday, September 7th. Seventeen equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Cepheid has a consensus rating of “Hold” and an average target price of $41.83.
Cepheid Company Profile
Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company’s systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures.
Receive News & Ratings for Cepheid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cepheid and related companies with MarketBeat.com's FREE daily email newsletter.